(Dad) Genentech Number Four

From: Earl Callen [mailto:earlcallen@yahoo.com]
Sent: Thursday, May 30, 2002 1:42 PM
To: Liza May
Subject: Re: Genentech Number Four

HEY! Right here in Kensington! This sounds good
to me. What do you think? dad


--- Liza May wrote:
> Dad, this is a multi-center trial, and from
> this it appears there is a
> Kensington location participating!!
> Love Liza
>
> Trial: Avastin (rhuMAb VEGF) plus chemotherapy
> in patients with metastatic
> colorectal cancer
>
>
> Maryland Locations:
>
> Baltimore, MD 21204 - Greater Baltimore Cancer
> Center
>
> Kensington, MD 20895 - Associates in
> Oncology/Hematology, PC
>
> Rockville, MD 20850 - Associates in
> Oncology/Hematology, PC
>
> Westminister, MD 21157 - Carroll County
> Cancer Center
>
>
>
> Rationale: rhuMAb VEGF (bevacizumab) is an
> experimental, humanized
> monoclonal antibody produced by Genentech,
> Inc., using recombinant DNA
> technology. rhuMAb VEGF is an antibody directed
> against vascular endothelial
> growth factor, or VEGF. VEGF is a potent,
> specific growth factor with a
> well-defined role in normal and abnormal blood
> vessel formation. It is
> present in a wide variety of normal tissues but
> is produced in excess by
> most solid cancers (tumors). In the setting of
> cancer, VEGF promotes the
> growth of blood vessels that bring nutrients to
> tumor cells. In laboratory
> studies, rhuMAb VEGF inhibits the growth of
> several different types of human
> cancer cells grown in animals by blocking the
> effects of VEGF.
> Purpose: The purpose of this study is to
> determine whether rhuMAb VEGF is
> safe and beneficial when given to patients with
> colorectal cancer in
> combination with the chemotherapy agents
> 5-fluorrouracil (5-FU) and
> leucovorin, and possibly followed by CPT-11
> (CAMPTOSAR, Irinotecan).
> Eligibility: Ability to provide written
> informed consent
> 18 years of age or older
> Confirmed colorectal cancer with evidence of
> metastases
> Willingness and capability to be acessible for
> long-term follow-up
> CPT-11 is appropriate as a first line of
> treatment for your cancer
>
> Treatment: The study consists of the following
> timelines:
> - A 28-day screening period
> - A treatment period that will last up to
> approximately 23 months
> - A 14-day followup period
> Additionally, basic information concerning
> disease condition will be
> collected following the study period.
> Content Provider: Genentech Corporation